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Abstract
Atherosclerosis is a chronic inflammatory process that leads to plaque formation in large and 
medium sized vessels. T helper 1 (Th1) cells constitute the majority of plaque infiltrating pro-
atherogenic T cells and are induced via IFNγ-dependent activation of T-box (Tbet) and/or IL-12-
dependent activation of signal transducer and activator of transcription 4 (STAT4). We thus aimed 
to define a role for STAT4 in atherosclerosis. STAT4-deficiency resulted in a ~71% reduction 
(p<0.001) in plaque burden in Stat4−/−Apoe−/− vs Apoe−/− mice fed chow diet and significantly 
attenuated atherosclerosis (~31%, p<0.01) in western diet fed Stat4−/−Apoe−/− mice. Surprisingly, 
reduced atherogenesis in Stat4−/−Apoe−/− mice was not due to attenuated IFNγ production in vivo 
by Th1 cells, suggesting an at least partially IFNγ-independent pro-atherogenic role of STAT4. 
STAT4 is expressed in T cells, but also detected in macrophages (MΦs). Stat4−/−Apoe−/− in vitro 
differentiated M1 or M2 MΦs had reduced cytokine production compare to Apoe−/− M1 and M2 
MΦs that was accompanied by reduced induction of CD69, I-Ab, and CD86 in response to LPS 
stimulation. Stat4−/−Apoe−/−MΦs expressed attenuated levels of CCR2 and demonstrated reduced 
migration toward CCL2 in a transwell assay. Importantly, the percentage of aortic 
CD11b+F4/80+Ly6Chi MΦs was reduced in Stat4−/−Apoe−/− vs Apoe−/− mice. Thus, this study 
identifies for the first time a pro-atherogenic role of STAT4 that is at least partially independent of 
Th1 cell-derived IFNγ, and primarily involving the modulation of MΦ responses.
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Introduction
Atherosclerosis is a disease of large and medium sized vessels that is accompanied by 
chronic inflammation in the arterial wall due to the involvement of the innate and adaptive 
immune responses1;2. While macrophages (MΦs) are known to be essential and the most 
prominent and abundant leukocyte subset within the atherosclerotic aorta1;3, several 
subpopulations of T cells are also detected within the atherosclerotic plaques, including T 
regulatory (Treg), T helper 1 (Th1), Th2, and Th17 cells, with IFNγ-producing Th1 cells 
being the most abundant4. Th1 cells release IFNγ causing the activation of MΦs and DCs, 
which generates a feedback loop leading to the Th1-driven pathogenesis and lesion 
amplification4;5.
The development and functions of Th1 cells are dependent on several transcription factors 
including the signal transducer and activator of transcription 4 (STAT4) and a member of 
the T box family of transcription factors, T-bet (Tbet/Tbx21)6-8. It was suggested that T-bet 
serves as a master regulator for the development of Th1 cells; however, STAT4 is also 
required for the complete differentiation of Th1 cells9. Additional evidence indicates that T-
bet and STAT4 might not be serving in a linear pathway and each factor can play a unique 
role in programming chromatin architecture for Th1 gene expression9. Significant reduction 
of Th1 cells via the deletion of Tbx21 attenuates lesion plaque formation in Tbet-deficient 
Ldlr−/− mice indicating a proatherogenic role of T-bet and Tbet-dependent Th1 cells in 
atherosclerosis10. While the role of T-bet in atherosclerosis is well established, the potential 
impact of STAT4 on atherogenesis is unclear.
IL-12 is one of the key cytokines that induces Th1 cell differentiation upon acute and 
chronic inflammation. Importantly, functional blockade of endogenous IL-12 by vaccination 
resulted in attenuated atherosclerosis accompanied by improved plaque stability11, 
indicating an important role of IL-12-dependent pathways during atherogenesis. IL-12 is a 
major factor for STAT4 phosphorylation in T cells resulting in their increased activation as 
well as development of fully functional Th1 cells and Type I IFNs are responsible for the 
activation of STAT4 in NK cells7;12. IL-23 is a cytokine that shares the IL-12p40 receptor 
subunit and activates the same JAK-STAT signaling molecules, but only weakly activates 
STAT413. Interestingly, STAT4 also limits Treg development14, and therefore is involved in 
the regulation of the delicate balance between Th1 and Treg cells. While, much of work on 
STAT4 has been performed in T cells, STAT4 is also expressed in the myeloid lineage, 
mainly in activated monocytes, MΦs, and DCs15.
In line with the involvement of STAT4 in the regulation of activity of leukocyte subsets, 
multiple reports demonstrated an important role of STAT4 in several pathological 
conditions. Mice that are deficient in Stat4 have decreased IFNγ production and are resistant 
to T cell-related autoimmune diseases such as experimental autoimmune 
encephalomyelitis16, type I diabetes17, and are susceptible to certain intracellular 
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pathogens7. Notably, recent studies also demonstrated an important role of the IL-12/STAT4 
axis in the regulation of vascular injury response18. STAT4-deficiency also decreases 
neointima formation under conditions of insulin resistance in obese Zucker rats19.
Based on the regulatory role of STAT4 in Th cell differentiation and myeloid cell activation/
functions, we hypothesized that STAT4 would play a role in atherosclerosis. Here, we 
demonstrate that STAT4-deficiency results in the attenuated MΦ activation, diminished 
aortic MΦ content, and reduced atherosclerosis in Stat4-deficient Apolipoprotein E-deficient 
(Stat4−/−Apoe−/−) mice. Interestingly, the effects of STAT4 are seen despite continued IFNγ 
production by Th1 cells.
Materials and Methods
Animals
Stat4−/− mice20 on the C57BL/6 background were cross-bred with Apoe−/− mice to generate 
Stat4−/−Apoe−/− mice. Seven week-old Stat4−/−Apoe−/− and Apoe−/− were fed a chow diet 
for 27 weeks or Western diet (21% fat and 0.15% cholesterol, Harlan Taklad, Harlan 
Laboratories, Indianapolis, IN) for 12 weeks. All animals were kept in specific pathogen-
free conditions, and animal experiments were approved by the Eastern Virginia Medical 
School Animal Care and Use Committee.
En Face
Aortas were harvested and stained for atherosclerotic lesions using Oil Red O as previously 
described21. Analysis of atherosclerotic area was determined by ImageJ software. Hearts 
were harvested then fixed with 4% PFA via cardiac puncture. Immunohistochemistry was 
conducted on sequential 5 μm aortic root sections cut from the point of appearance of the 
aortic valve leaflets21. Six sequential 5 m-thick aortic root sections >150μm were collected 
and analyzed by Russell modified-Movat staining as previously described21.
Measurement of plasma lipids
Total plasma cholesterol levels, plasma HDL and LDL were determined using Wako 
colorimetric kits and protocol (Wako Diagnostics, Wako Chemicals USA Inc., Richmond, 
VA).
Quantitative real time PCR
Total RNA was extracted from splenic cells and MΦs using Trizol® reagent (Invitrogen™, 
Life Technologies, Grand Island, NY). DNase I treatment using RNeasy kits was used to 
remove contaminating genomic DNA (Qiagen, Germantown, MD). Splenic RNA: 
Approximately 1 μg of total RNA was reverse transcribed to cDNA by synthesis reactions 
containing random hexamers, 10 mM dNTPs, Moloney murine leukemia virus reverse 
transcriptase (MMLV), 0.1 M DTT, and 5×1st strand buffer (Sigma-Aldrich, St. Louis, MO). 
Real time PCR was performed using Taqman probes from Applied Biosystems (Carlsbad, 
CA), 10 mM dNTPs, 10× PCR buffer without MgCl2, MgCl2, and Jumpstart Taq 
polymerase (Sigma-Aldrich, St. Louis, MO) for Ifnγ and Il17a for splenic cells, and iNos, 
Mrc1, Arg1, and Retnla for MΦs. Ct values for cDNA were determined using a CFX96™ 
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Real-Time System C1000™ Thermal Cycler detection system (Bio-Rad laboratories). The 
results were normalized to housekeeping gene Actb or 18S.
Flow Cytometry
Single cell suspensions from the aorta were prepared as previously described21. Briefly, 
mice were anesthetized using CO2, blood was collected via cardiac puncture and 
erythrocytes were lysed using ACK lysing buffer (8.29mg/ml NH4CL, 1mg/ml KHCO3, 
0.372mg/ml EDTA, all from Sigma-Aldritch). Next, the heart was perfused with PBS 
containing 20 U/ml of heparin by cardiac puncture. Aortas were then microdissected and 
enzymatically digested for 1 hour at 37°C with 125 U/ml Collagenase type XI, 60 U/ml 
hyaluronidase type I-s, 60 U/ml DNAse1 and 450 U/ml Collagenase type I (Sigma-Aldrich, 
St. Louis, MO) in PBS as described previously21. Aortas, spleens, and peripheral lymph 
node (PLN), were delicately rubbed in a 70 μm cell sieve (Corning Incorporated Life 
Sciences, Tewksbury, MA). Cell numbers were determined using trypan blue (MP 
Biomedicals, LLC, Solon, OH) and the hemocytometer. For intracellular cytokine staining, 
splenic and aortic cell suspensions were cultured for 5 hours in RPMI 1640 supplemented 
with 10% FBS, 1% Penicillin/Streptomycin, 10 ng/ml PMA, 500 ng/ml calcium ionophore 
and GolgiStop (BD Biosciences, San Jose, CA). Intracellular staining for IFNγ and IL-17A, 
as well as CD68 was performed according to the Fix&Perm® cell permeabilization protocol 
(BD Biosciences, San Jose, CA). The Cytek DXP 8 Color (Cytek Development Inc.) 
upgraded FACSCalibur™ (BD Biosciences, San Jose, CA) was used to collect samples and 
data analysis was conducted with FlowJo (Tree Star Inc., Ashland, OR). In all flow 
cytometry experiments isotype control and fluorescent minus one control were used to set 
appropriate gating for the samples.
Bone marrow-derived macrophages (BMDM)
BMDM were isolated according to Zhang et al.22. Briefly, femurs were cleaned of tissue 
then cut at joints exposing the bone marrow cavity. Cold PBS was flushed through the 
cavity. Cells were plated in DMEM/F12 media with 10ng/mL GM-CSF for 7 days. On day 
3, the media was then re-supplemented with 10ng/mL GM-CSF.
Macrophage and BMDM polarization
Briefly, cells were plated in complete RPMI-1640 supplemented media with 10% FBS, 1% 
Penicillin/Streptomycin, 1% Glutamax, 1% Hepes, 0.5% NEAA, 0.5% Sodium pyruvate, 
and 50 μM BME for 2 hours. Thioglycollate was not used for the isolation of peritoneal 
cells. Lymphocytes were removed by washing with complete media. To prime classical 
M1s, IFNγ (150 U/mL) was added to complete media and incubated for 6 hours. Then M1s 
were stimulated by adding LPS (100 ng/mL) for 16 hours. M2 were primed by adding IL-4 
(20 U/mL and IL-13 (15 U/mL) in complete media to cells and incubated overnight. Then 
supernatants for both M1 and M2 were collected and cytokines were detected using IL-10, 
IL-12p70, IFNγ, TNFα, CCL2, and CXCL10 Flow Cytomix assays (eBioscience, San 
Diego, CA). Data are presented as a fold change compared to the control Apoe−/− (1 fold). 
Stat4−/− and wild type BMDM were activated with Heat-killed methicillin resistant 
Staphylococcus aureus (HK-MRSA, generously provided by Dr.Serezani, Indiana 
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University) (10 bacteria: 1 macrophage) for 24 hours, then incubated with IL-12 (5 ng/mL) 
for 6 hours and stimulated with LPS (100 ng/mL) for 18 hours. Cytokine concentrations 
were determined by multiplex assay for IL-10, IFNγ, TNFα, CCL2 and CXCL10.
LPS stimulation
Splenic cell suspensions were cultured in complete RPMI-1640 supplemented media with 
10% FBS, 1% Penicillin/Streptomycin, 1% Glutamax, 1% Hepes, 0.5% NEAA, 0.5% 
Sodium pyruvate, 50 μM BME, and LPS (5 μg/mL) for 16 hours. Cells were stained with 
anti-CD86, CD11b, and MHC-II (I-Ab) Abs and analyzed by flow cytometry. Data are 
presented as a fold change (percentage of positive cells) compared to the control Apoe−/− (1 
fold).
Th1/Treg polarization
Naive splenic CD4+ cells from Stat4−/−Apoe−/− and Apoe−/− mice were isolated via MACS 
Miltenyi Biotec CD4+CD62+ T Cell Isolation Kit II mouse following manufacturer's 
protocol (Auburn, CA). Naive CD4+ cells were plated on α-CD3 (5 μg/mL) coated plates. 
RPMI-1640 supplemented media with soluble α-CD28 (1 μg/mL) 10% FBS, 1% Penicillin/
Streptomycin, 1% Glutamax, 1% Hepes, 0.5% Non-Essential Amino Acids (NEAA), 0.5% 
Sodium pyruvate, 50 μM BME, and IL-12 (10 ng/mL) or TGFβ (5 ng/mL) was added in the 
cultures to polarize towards Th1 or Treg cells, respectively. After 3 days, cells were 
collected and stained for CD4+, IFNγ, and FoxP3 using Foxp3/Transcription Factor Staining 
Buffer Set (eBioscience, San Diego, CA).
Dyes, recombinant proteins and antibodies
The antibodies used were as follows: Ly6C-FITC (AL-21), CD68-PE (FA11), IL-17A-PE 
(TC11-18H10), CD45-PerCP (30-F11), CD11b-PB (M1/70.15), IFNγ-eFluor 450 
(XMG1.2), CD4-PerCP (L3T4), F4/80-APC-eFluor780 (BM8), Foxp3-PE (MF23), CD3-
APCCY7/eFluor780 (17A2), Ly-6G-PE (1A8), anti-mCCR2- FITC (R&D Systems), and 
anti-mouse CD16/CD32 (The Lymphocyte Culture Centre, UVA, Charlottesville, VA). To 
distinguish between live and dead cells, Viability Live Dead-ef650 (eBioscience, San Diego, 
CA) was used. Recombinant proteins used were as followed: mouse IL-4, IL-13, IL-12, 
IFNγ, TGFβ were purchased from PeproTech (Rocky Hill, NJ). LPS was purchased through 
Sigma-Aldrich (St. Louis, MO).
In vitro migration assay
A migration assay was performed using 5-μm 24-well plates (Costar). Recombinant 50 
ng/mL of CCL2 in 600uL of 1% FBS in RPMI-1640 medium (PeproTech (Rocky Hill, NJ.) 
was placed in the low chamber. A total of 0.5×106 Stat4−/−Apoe−/− or Apoe−/− splenocytes 
in 100 μl of 1% FBS in RPMI-1640 medium were placed on the upper wells of Transwell 
membranes. Plates were incubated for at 37°C and 5% CO2 atmosphere. After 3 hrs of 
incubation the upper wells were carefully removed and migrated cells in the bottom wells 
were collected, stained with Trypan-Blue, and counted under light microscope. Next 
migrated cells were stained with a combination of Abs against CD11b, CD4, and F4/80 and 
the percentage of migrated CD4+, CD11b+ and CD11b+/F4/80+ cells was determined using 
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flow cytometry. The rate of cell migration was expressed as a migration index (%): (number 
of emigrated cells toward CCL2+ wells divided by the number of migrated cells in control 
CCL2-negative wells.
Statistical Analysis
Data were analyzed by Graphpad Prism6, comparisons were made using unpaired Student's 
or Mann-Whithey test with the data expressed as mean±SEM. Comparisons of three or more 
groups were conducted using an ANOVA and multiple comparisons using TUKEY test. 
Statistical significance was set at p<0.05.
Results
Stat4-deficiency has limited effects on T helper development during atherosclerosis
To investigate the role of STAT4 in atherosclerosis, we generated Stat4-deficient Apoe−/− 
(Stat4−/−Apoe−/−) mice. STAT4 is one of the key transcription factors that regulates the 
balance between Treg, Th1, and Th17 cells7. Therefore, we first tested the impact of STAT4 
deficiency on the ability of Stat4-deficient CD4+ cells to differentiate into IFNγ-expressing 
Th1 cells and Tregs under Th1 and Treg polarizing conditions in vitro and in 
atherosclerosis-prone conditions in Apoe−/− mice. In vitro-generated Th1 cells from 
Apoe−/− mice demonstrated a significant expression of IFNγ, while STAT4-deficiency 
resulted in a 90% reduction in Th1 cell differentiation (Fig.1A) confirming a critical role of 
the IL-12/STAT4 axis in IFNγ induction in vitro20;23. In contrast, there were no significant 
differences between percentage (Fig.1B-C) or numbers of IFNγ+CD4+ cells from spleens 
(Stat4−/−Apoe−/− 1.0±0.3×106 vs Apoe−/− 1.2±0.1×106 cells) and peripheral lymph nodes 
(Stat4−/−Apoe−/− 1.8±0.3×105 vs Apoe−/− 1.5±0.3×105 cells) of Stat4−/−Apoe−/− and 
Apoe−/− mice by flow cytometry (Fig.1B-C). We also detected no difference in Ifnγ 
expression in the spleens by RT-PCR analysis (Fig.1D).
STAT4 might also alter the homeostasis of Tregs, which have been demonstrated to play an 
important atheroprotective role24. To test the potential impact of STAT4-deficiency on Treg 
differentiation, we examined Treg differentiation under Treg-polarization conditions in vitro 
and compared Stat4-deficient Tregdifferentiation with that of the control Apoe−/− mice. 
STAT4-deficiency allowed more robust Treg differentiation of Stat4−/−Apoe−/− CD4+ cells 
in comparison with Apoe−/− cells (Fig.1E) supporting a role of STAT4 in Treg 
differentiation in vitro. Unexpectedly, no differences in Foxp3+ Treg frequency (Fig.1F and 
G) or numbers were found within the PLNs (Stat4−/−Apoe−/− 1.1±0.1×106 ± vs Apoe−/− 
1.4±0.1×106 cells, n=12-15) and spleens (Stat4−/−Apoe−/− 2.4±0.4×106 ± vs Apoe−/− 
3.0±0.3×106 cells, n=11-15) of Stat4−/−Apoe−/− and Apoe−/− mice (Fig.1G). Thus, the 
abolishment of STAT4 supports Treg formation and reduces Th1 cell differentiation in vitro, 
but has no effects on Treg and Th1 cell development during atherosclerosis. Interestingly, 
these results suggest an existence of additional pathway(s) that contributes to the Th1 cell 
development in the absence of STAT4 signaling upon atherosclerotic conditions in vivo.
Evidence suggests a requirement of STAT4 for the development of Th17 cells6. It has also 
been shown that the development of atherosclerosis is accompanied by increased 
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differentiation of IL-17-expressing cells including Th17 and γδ+IL-17+ T cells21. To 
determine whether STAT4-deficiency results in attenuated levels of Th17 cells, we analyzed 
the mRNA expression of Il17a and conducted FACS analysis of splenic cells and found no 
difference in the percentage of IL-17A+CD4+ cells (Suppl.Fig.1) or mRNA expression of 
Il17a in the spleens between Stat4−/−Apoe−/− and −Apoe−/− mice (Fig.1H).
Stat4−/− deficiency has no effects on M1 and M2 macrophage polarization, but attenuates 
macrophage activation and pro-inflammatory cytokine production, as well as macrophage 
migration to CCL2
Since STAT4 expression was previously reported for activated monocytes, we next sought 
to test whether STAT4-deficiency affects MΦ M1 and/or M2 polarization and the functional 
activity of M1 and M2 MΦs. Upon M1 polarizing conditions, Apoe−/− MΦs properly 
polarized to the M1 phenotype based on the upregulation of iNOS (Fig.2A) and CCL2 
(Suppl.Fig.2). Interestingly, Stat4−/−Apoe−/− MΦs also successfully polarized into M1 MΦs 
and expressed similar levels of iNOS compared to Apoe−/− MΦs (Fig.2A). M2 polarizing 
conditions effectively induced the differentiation of both Stat4−/−Apoe−/− and Apoe−/− MΦs 
towards the M2 phenotype based on the expression of well-known M2 markers such as 
CD206, Arg1, and Fizz (gene expression: Mrc1, Arg-1, Retnla, respectively). Thus, STAT4-
deficiency does not affect the differentiation of MΦs to either M1 or M2 phenotype.
To further examine the potential impact of STAT4-deficiency on bone-marrow-derived MΦ 
activation, we examined the production of several cytokines and the chemokine CCL2 upon 
LPS stimulation supported by IL-12 and HK-MRSA, are well-known stimuli for cytokine 
production by MΦs. We also sought to confirm that the differences between wild type and 
Stat4−/− were the same when even the ApoE mutant allele was not present. As demonstrated 
in Fig.2B, STAT4-deficient MΦ displayed attenuated production of several cytokines 
including TNFα, IFNγ, IL-10 and chemokines CCL2 and CXCL10. Next to further get 
insight to an impact of STAT4-deficiency on MΦ functions, we examined the activation 
status of splenic CD11b+ MΦs in the response of LPS, a common MΦ activator. After LPS 
stimulation, Stat4−/−Apoe−/− MΦs demonstrated reduced expression of the co-stimulatory 
molecule CD86, and the early activation marker CD69 compared to Apoe−/− MΦs, 
suggesting that STAT4-deficiency affects TLR4-dependent MΦs activation (Fig.2C).
While the results obtained from bone-marrow differentiated STAT4-deficient MΦs clearly 
indicated defective activation and pro-inflammatory cytokine/chemokine production upon 
stimulation, we also sought to test whether peritoneal MΦs that is another source of MΦs 
will display similar behavior. We analyzed the production of several cytokines and 
chemokines in peritoneal MΦs isolated from Stat4−/−Apoe−/− and Apoe−/− mice. STAT4-
deficient peritoneal MΦs displayed significant reductions of CCL2 (203±20 pg/ml vs 
1011±172 pg/ml, Stat4−/−Apoe−/− and Apoe−/− MΦs, respectively, p=0.05) and therefore 
decreased ratio of CCL2 expression from Stat4−/−Apoe−/− vs Apoe−/− MΦs at the basal 
levels (Fig.3A). Two specific lineages of macrophages, M1 and M2, can inversely affect 
atherosclerosis development through the release of unique sets of M1 and M2-specific 
cytokines. M1 MΦs release high levels of IL-12, IFNγ, TNFα, CCL2, and CXCL10 and thus 
likely play a pro-atherogenic role25. In contrast, M2 MΦs serve as anti-inflammatory and 
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anti-atherogenic via the release of high levels of IL-10 and TGFβ. While STAT4-deficiency 
did not influence the capacity of STAT-4-deficient MΦs to differentiate into M1 or M2 MΦs 
upon M1/M2 polarizing conditions (Fig.2A), Stat4−/−Apoe−/− MΦs displayed decreased 
levels of IFNγ and CXCL10 (Fig.3B) and CCL2 (Suppl.Fig.2) compared to M1 MΦs from 
Apoe−/− mice. It might be possible that reduced IFNγ levels in Stat4−/−Apoe−/− M1 MΦs 
results in subsequent attenuated levels of CCL2 and CXCL10, the induction of which is 
strongly regulated by IFNγ. Interestingly, polarized Stat4−/−Apoe−/− M2 MΦs secreted 
similar levels of IL-10, but reduced levels of CCL2 and CXCL10 compared to Apoe−/− M2 
MΦs (Fig.3C). These data suggest that STAT4-deficiency did not affect on M1/M2 
polarization, but had important actions to reduce a proper MΦ activation (CD86 and CD69 
expression) and production of several cytokines and chemokines.
Next, to determine potential impact of STAT4-deficiency on migratory responses of splenic 
CD11b+ myeloid cells to CCL2, we used a transwell assay. As expected, migration of 
Apoe−/− CD11b+F4/80+ macrophages was detected in response to recombinant CCL2 (Fig.
4A, B). However, the percentage of migrated STAT4-deficient CD11b+F4/80+ MΦs was 
decreased (Fig.4A). Similarly, the index of migration toward CCL2 was elevated for Apoe−/
− CD11b+F4/80+ MΦs (Fig.4B). In contrast, we found no increase in the index of migration 
for Stat4−/−Apoe−/− CD11b+F4/80+ MΦs (Fig.4B). To get further insight into a potential 
mechanism of changes in responsiveness to the CCL2-mediated migration; we examined the 
expression of CCR2, the chemokine receptor that recognizes CCL2. As demonstrated in Fig.
4C-D, we detected reduced levels of CD11b+F4/80+ MΦs expressing CCR2 isolated from 
spleen and blood of Stat4−/−Apoe−/−mice. Altogether, these results indicate that STAT4 
deficiency attenuates CCR2 expression and the subsequent migration of CD11b+F4/80+ 
MΦs towards CCL2.
STAT4-deficiency reduces the development of atherosclerosis in Stat4−/−Apoe−/− mice
To further test a role of STAT4 in atherosclerosis, we analyzed plaque size in the aortas of 
40 week old Stat4−/−Apoe−/− female mice fed a chow diet and detected a major 71% 
reduction of aortic lesions in comparison with control Apoe−/− mice (Fig.5A). Lesion area 
was decreased from 22.8±3.7% to 6.4±0.4% (p<0.01). Similarly, we detected a 60% 
reduction in plaque burden when atherosclerosis was evaluated in male Apoe−/− versus 
Stat4−/−Apoe−/− male (13.2±0.9% and 5.3±0.5%, respectively, p<0.001). The percentage of 
plaque area within the aortic roots of 40-41 weeks old mice fed chow diet was also 
decreased in Stat4−/−Apoe−/− vs Apoe−/− mice (Fig.5B). STAT4 deletion also significantly 
reduced atherosclerosis in western diet fed Stat4−/−Apoe−/− mice vs age and diet-matched 
Apoe−/− mice (p<0.01, Suppl. Fig.4, total cholesterol levels 793.5±28.0 mg/dL vs 
711.6±15.3 mg/dL, n=10 and 10, respectively). Chow diet fed 40 week old Stat4−/− Apoe−/− 
and Apoe−/− mice had no difference in body weight, total cholesterol, HDL and LDL levels 
(Suppl.Table 1). These results clearly demonstrated an important role for STAT4 in 
atherosclerotic plaque formation in Apoe−/− mice.
To further understand the potential mechanism through which STAT4-deficiency reduces 
plaque formation, we examined the aortic immune composition with a specific focus on T 
cells and MΦs. STAT4-deficiency was associated with a reduction in local aortic 
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inflammation, as revealed by the significant decrease of CD11b+F4/80+ MΦs and highly 
pro-inflammatory CD11b+F4/80+Ly6Chigh MΦs within the aortas of Stat4−/−Apoe−/− mice 
(Fig.5C). This proportional reduction in MΦ was also detected in the spleens of 
Stat4−/−Apoe−/−compared with Apoe−/− mice (Suppl.Fig.3A). Interestingly, the percentage 
of Ly6Chigh pro-inflammatory monocytes, but not the Ly6Clow/neg patrolling monocytes was 
reduced in the blood of Stat4−/−Apoe−/− mice (Suppl.Fig.3B) suggesting that reduced MΦ 
frequency in the aortas of Stat4−/−Apoe−/− mice is likely due to diminished pool of 
peripheral blood pro-inflammatory monocytes and attenuated CCR2-dependent migration of 
monocytes to the atherosclerotic plaques of Stat4−/−Apoe−/− mice.
As STAT4 plays an important role in NK cell biology, we examined the effects of STAT4 
deficiency on NK cell content in the aorta and secondary lymphoid tissues and found no 
difference in the percentage and numbers of NK cells between Stat4−/−Apoe−/− and 
Apoe−/− mice (data not shown). Additionally, the percentage of CD3+ T cells in the aortic 
total leukocyte population was similar between Stat4−/−Apoe−/− and Apoe−/− mice (data not 
shown). While STAT4 deficiency dramatically reduced the differentiation of IFNγ-
expressing Th1 cells and supported Treg differentiation under Th1 and Treg polarizing 
conditions in vitro, to our surprise, we found no difference in the percentage of IFNγ+ Th1 
or Treg cells between the aortas of Stat4−/−Apoe−/− and Apoe−/− mice by flow cytometry 
(Fig.5D) or RT-PCR analysis (data not shown). Thus, although STAT4-deficiency is clearly 
protective during atherogenesis, and this phenotype, at least partially, is independent from 
IFNg+Th1 and Treg cell abundance in vivo.
Discussion
The requirement for immune responses at all stages of atherogenesis is well-established; 
however, the detailed mechanisms that guide leukocyte activation and differentiation are not 
completely understood1;4. An increasing body of evidence suggests that the JAK/STAT 
signaling is an important regulator of atherosclerosis and tissue remodeling in response to 
injury26. STAT4, a member of the STAT family, plays a critical role in inflammation and 
several autoimmune diseases including autoimmune myocarditis27, cystic fibrosis28, 
sepsis29, cardiac allograft vasculopathy30, allergic airway inflammation31, experimental 
autoimmune encephalomyelitis, autoimmune diabetes17, and high fat diet-induced obesity32. 
To date, the role of STAT4 in atherosclerosis remains unclear. The current study 
demonstrates for the first time that STAT4 is a pro-atherogenic factor, which regulates 
atherogenesis, at least partially, in a Th1-IFNγ-independent manner via the modulation of 
MΦ content within the aortic wall.
Pro-atherogenic Th1 cells require Tbet and STAT4 for their successful differentiation and 
full spectrum of functions. T cell receptor (TCR)-dependent expression of IFNγ induces 
STAT1 activation and a subsequent activation of Tbet, resulting in the expression of 
IL-12Rβ2 chain whereas IL-12 promotes STAT4 activation and is associated to effector 
functions of Th1 cell differentiation9;33. Thus, there are two major pathways that regulate 
Th1 cell differentiation: TCR/IFNγ/Stat1/Tbet and IL-12/STAT4/Tbet. STAT4-deficient 
naïve CD4+ cells display attenuated IFNγ+Th1 cell differentiation and increased levels of 
Foxp3+ Treg generation in response to Th1 and Treg polarizing conditions in vitro 
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demonstrating the important role of Stat4 in Th cell balance14;34;35. We confirm these 
results and show a 10-fold decrease in the induction of Stat4-deficient IFNγ+CD4+ Th1 cells 
and a 1.7-fold increase in Stat4-deficient Foxp3+ CD4+ Tregs in vitro. In contrast, similar 
levels of CD4+IFNγ+ cells are detected within the spleen, PLNs, and the aorta of 
Stat4−/−Apoe−/− mice, suggesting that mechanisms for the reduction of atherosclerosis in 
Stat4−/−Apoe−/− mice may be at least partially IFNγ-independent. Several models of 
experimental colitis and autoimmune myocarditis demonstrate a key role of the IL-12/
STAT4 signaling pathway; however the pathology of the disease is IFNγ-
independent35;36,27. These studies suggest that STAT4 may have an additional impact on the 
inflammatory processes that are not tightly related to the induction of IFNγ expression in T 
cells. It is possible that STAT4 affects other properties of Th1 cells, such as TNFα, IL-6 and 
chemokine production or T cell migration, that play a key role in the progression of many 
diseases, including atherosclerosis. Interestingly, these data also suggest that Tbet is a major 
transcription factor that drives IFNγ+ production and Th1 polarization in atherosclerosis.
STAT4 is constitutively expressed in T and NK cells, but upon activation with IFNγ or LPS, 
monocytes and dendritic cells express high levels of STAT415. Interestingly, STAT4 is 
phosphorylated in response to IFNα but not IL-12 in human monocytes15. Importantly, 
activated macrophages within synovial tissues obtained from patients with rheumatoid 
arthritis express high levels of STAT4 suggesting that these myeloid cells might have a role 
in a prototypical Th1-driven human disease15. Importantly, Stat4-deficient MΦs have 
diminished microbicidal activity, low nitric oxide NO, and IFNγ production37. In this study, 
we show that Stat4-deficient peritoneal or bone-marrow derived MΦs are capable to 
differentiate into M1 and M2 MΦs in vitro, but ex vivo isolated Stat4-deficient MΦs release 
attenuated levels of CCL2, and in vitro generated M1 and M2 MΦs produce low levels of 
IFNγ, CCL2 and CXCL12. These results suggest that STAT4 in MΦs regulates the 
recruitment of monocytes and T cells via the regulation of specific aortic chemokine 
microenvironments. To date, mechanisms by which STAT4 modulates MΦ activity are not 
clearly defined. One of the potential pathways that would be responsible for the low 
production of pro-inflammatory stimuli by Stat4-deficient MΦs could be diminished levels 
of activation/responsiveness upon stimulation. In line with this hypothesis, we found an 
attenuated expression of CD69 and CD86 by Stat4-deficient MΦs upon in vitro LPS 
stimulation and low levels of IFNγ and several chemokines. Relevant to our observed 
phenotype, a study had also revealed an important role of STAT4 in modulation of TLR4-
mediated MΦs activation38.
MΦs are essential components of atherosclerotic plaques and their presence and activation 
status strongly correlates with the disease progression. Our study demonstrates that the 
aortas from Stat4−/−Apoe−/− mice contain decreased percentages of CD11b+F4/80+ MΦs 
within the aortic leukocyte population suggesting that STAT4 is involved in the regulation 
of MΦ numbers in aortas. Since Stat4−/−Apoe−/− MΦs displayed the attenuated expression 
of CCR2 and reduced migration towards CCL2, we imply that STAT4 regulates CCL2/
CCR2-dependent recruitment of MΦs into the aorta. In line with this data, we have also 
shown that Stat4−/−Apoe−/− MΦs produce low levels of CCL2, one of the major 
chemokines regulating monocyte migration to the aorta39. This study also highlighted a 
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potential role of STAT4 in the regulation of peripheral blood Ly6Chigh monocytes that are 
known to be important players in atherosclerosis. Interestingly, we also found low levels of 
F4/80+CD11b+ myeloid cells in the spleen of Stat4−/−Apoe−/− mice. The role of splenic 
monocytes as a second reservoir for monocyte-derived MΦs in atherosclerotic plaques has 
been demonstrated40. There are several potential mechanisms that may account for a 
reduced MΦ content in Stat4−/−Apoe−/− aortas including attenuated migration of monocytes 
from peripheral blood or the spleen or reduced local proliferation within the atherosclerotic 
vessel. Further studies will be necessary to explore the complex relationship between 
circulating, splenic monocytes and MΦ content in the aorta.
Conclusion
In this study, we report a pro-atherogenic role for the transcription factor STAT4 in the 
development of atherosclerosis in Apoe−/− mice. STAT4 is an important transcription factor 
for the Th1 cell generation; however, in this study STAT4-deficiency has limited effects on 
the Th1 cell content indicating that there are some compensatory mechanisms that support 
STAT4-deficient Th1 cell development in the conditions of atherosclerosis. Our study 
demonstrates that STAT4-deficiency primarily affects MΦ activation and CCL2-induced 
MΦ migration as well as aortic macrophage content. These findings suggest a novel 
mechanism by which the transcription factor STAT4 influences the development of 
atherosclerosis in, at least partially, an IFNγ-independent manner through the alteration of 
immune composition within the aortic wall. This work has important implications for our 
understanding of mechanisms of atherosclerosis. The results suggest that targeting STAT4 
or key downstream targets could provide novel therapeutic opportunities to prevent 
atherosclerosis.
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• Stat4−/−Apoe−/− deficient mice were generated
• Stat-4 deficiency resulted in the attenuated atherosclerosis
• Reduced atherogenesis was at least partially independent of Th1 cell-derived 
IFNγ
• STAT4 supports pro-inflammatory macrophage response in atherosclerosis
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Figure 1. Distinct effects of Stat4 on T cell differentiation and macrophage activation
(A, E) Naïve T cells from Stat4−/−Apoe−/− and Apoe−/− mice were cultured under Th1 (A) 
or Treg (E) polarizing conditions and analyzed for IFNγ and Foxp-3 expression, 
respectively. Representative FACS plots on gated CD4+ cells from FACS are shown. (B, C, 
F and G) Spleens and PLNs from Stat4−/−Apoe−/− and Apoe−/− mice were analyzed for the 
expression of IFNγ+ and Foxp3+ by CD4+ cells (n=12). Representative FACS plots on gated 
CD4+ cells are shown. (C, G) Total percentage of CD4+IFNγ+ and Foxp3+ Tregs in spleens 
and PLNs (n=12). (D, H) mRNA from spleens was extracted and analyzed for Ifnγ and Il17a 
(n=5 and 6). *P<0.05, **P<0.01, ***P<0.001, and ****P<0.0001.
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Figure 2. Stat4−/− deficiency has no effects on M1 and M2 macrophage polarization, but 
attenuates macrophage activation and pro-inflammatory cytokine production, as well as 
macrophage migration to CCL2
(A) Bone marrow cells were cultured with 10 ng/mL GM-CSF for 7 days, then cultured 
under either M1 or M2 conditions. PCR was conducted to determine MΦ polarization 
effectiveness by examination of iNos, Mrc1, Arg1, and Retnla expression by M1 and M2 
Stat4−/−Apoe−/− and Apoe−/− MΦs (n=4). (B) Stat4−/− (black bar) and wild type (grey bar) 
BMDM were incubated with heat-killed methicillin resistant Staphylococcus aureus (HK-
MRSA) for 24 hours, incubated with IL-12 for 6 hours and stimulated with LPS for 18 
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hours. Cytokine concentrations were determined by multiplex assay. (C) Splenic cells were 
cultured with LPS for 16 hours, and the expression of CD86, I-Ab, and CD69 was 
determined by flow cytometry. Results show a ratio of percentages of positive CD86, I-Ab, 
and CD69 MΦs between Stat4−/−Apoe−/− and Apoe−/− cells (n=6).
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Figure 3. Stat4−/−Apoe−/− peritoneal macrophages display attenuated pro-inflammatory 
cytokine response
(A-C) Peritoneal macrophages were isolated and cultured under either non-polarizing (A), or 
(B) M1 or (C) M2 conditions. The media was examined for soluble IL-10, IL-12p70, IFNγ, 
TNFα, CCL2, and CXCL10. Results show mean±SE as the ratio of Stat4−/−Apoe−/− (black 
bar) to Apoe−/− (grey bar) per independent experiment (n=4). *P<0.05, **P<0.01, 
***P<0.001, and ****P<0.0001.
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Figure 4. Stat4 deficiency diminishes the migration of CD11b+ F4/80+ splenic macrophages 
towards CCL2
(A) Representative FACS plots of the transwell migration of CD11b+F4/80+Live+ splenic 
MΦs from Apoe−/− and Stat4−/−Apoe−/− mice towards 50ng/mL of CCL2. (B) 
CD11b+F4/80+Live+ migration index with or without CCL2. (C) Ex vivo splenic cells from 
Apoe−/− and Stat4−/−Apoe−/− mice stained for CD11b+CCR2+Live+ (n=5 and 6). (D) 
Peripheral blood stained for CD11b+F4/80+CCR2+Live+ cells from Apoe−/− and 
Stat4−/−Apoe−/− mice (n=5 and 6). * P<0.05, **P<0.01.
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Figure 5. Stat4 deficiency reduces atherosclerosis and alters macrophage but not IFNγ+Th1 cell 
content in the aortas
(A) Representative en face ORO staining of aortas from aged female Stat4−/−Apoe−/− and 
Apoe−/− mice. Lesion sizes (% of whole aorta) were determined and each symbol represents 
one animal, horizontal bars represent means. (B) Representative MOVAT aortic root 
sections from aged female Stat4−/−Apoe−/− and Apoe−/− mice fed a CD. Plaque area was 
determined (mm2). Each symbol represents one animal, horizontal bars represent means. (C) 
Aortic cell suspensions were stained with anti-CD11b, -Ly6C, -CD68, -F4/80, and -CD45 
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Abs (n=10). (D) The total percentage of CD4+IFNγ+ cells in aortas of Stat4−/−Apoe−/− 
(black bar) and Apoe−/− (grey bar) mice (n=7). * p<0.05, ** p<0.01
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Table 1
Body weights, total cholesterol, total triglycerides, and HDL and LDL levels in Stat-4−/−Apoe−/− and Apoe−/− 
mice on chow diet.
Stat4−/−Apoe−/− Apoe−/−
Body Weights, grams 27.69±0.51* 23.60±0.56
Total Cholesterol, mg/dL 272.2±17.7 248.5±19.6
HDL, mg/dL 60.7±6.5 57.2±9.5
LDL, mg/dL 149.4±14.5 130.2±11.7
Data are presented as mean±SEM for BW n=28 and 21 mice and lipids n=10 mice for each genotype. Plasma of fasted 34 week old female mice 
was analyzed for total cholesterol, triglycerides, and HDL, LDL levels.
*
P<0.00001
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